LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.
Current Value
$51.281 Year Return
Current Value
$51.281 Year Return
Market Cap
$2.79B
P/E Ratio
120.51
1Y Stock Return
18.18%
1Y Revenue Growth
10.69%
Dividend Yield
0.00%
Price to Book
2.1
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VTYX | 46.31% | $125.87M | -23.61% | 0.00% |
GRMN | 44.34% | $39.82B | +73.79% | 1.43% |
RWT | 41.88% | $941.74M | +5.01% | 9.17% |
LC | 41.21% | $1.69B | +175.00% | 0.00% |
LXP | 40.79% | $2.70B | +9.82% | 5.66% |
TRTX | 40.34% | $716.21M | +56.64% | 10.91% |
CVBF | 40.11% | $3.14B | +26.78% | 3.58% |
NRDS | 40.09% | $984.08M | +21.93% | 0.00% |
CTS | 39.54% | $1.58B | +33.53% | 0.30% |
USNA | 39.06% | $744.09M | -16.12% | 0.00% |
STHO | 38.92% | $150.51M | -5.99% | 0.00% |
SRDX | 38.66% | $559.12M | +15.64% | 0.00% |
ATEN | 38.41% | $1.21B | +34.32% | 1.46% |
VBTX | 38.28% | $1.58B | +53.68% | 2.75% |
TRN | 38.22% | $3.12B | +54.58% | 2.95% |
SCL | 38.10% | $1.69B | -6.79% | 2.01% |
CNDT | 38.04% | $569.21M | +20.27% | 0.00% |
PLYM | 38.01% | $842.88M | -11.32% | 5.12% |
AORT | 37.90% | $1.13B | +69.69% | 0.00% |
HTH | 37.88% | $2.06B | +6.37% | 2.16% |
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
QXO | -15.53% | $6.51B | -35.95% | 0.00% |
TPST | -15.16% | $37.75M | -77.59% | 0.00% |
HUSA | -14.60% | $16.69M | -11.56% | 0.00% |
COR | -14.41% | $47.48B | +21.20% | 0.86% |
CODX | -12.82% | $34.16M | -25.17% | 0.00% |
GME | -11.39% | $11.76B | +119.68% | 0.00% |
CME | -10.45% | $82.76B | +9.21% | 1.98% |
MCK | -9.49% | $78.15B | +35.51% | 0.42% |
STG | -8.19% | $35.67M | +7.92% | 0.00% |
LMT | -7.64% | $126.40B | +18.99% | 2.36% |
RBRK | -7.54% | $8.03B | +38.16% | 0.00% |
IMMP | -7.22% | $293.82M | +8.31% | 0.00% |
CORZ | -7.08% | $4.60B | +3,201.26% | 0.00% |
RDDT | -5.90% | $24.08B | +303.41% | 0.00% |
AVAL | -5.85% | $791.37M | -4.11% | 7.14% |
PANW | -5.70% | $126.99B | +46.98% | 0.00% |
PRPO | -5.63% | $9.10M | -13.65% | 0.00% |
TXO | -5.53% | $737.26M | -1.80% | 13.22% |
FENG | -5.51% | $13.37M | +96.77% | 0.00% |
CHD | -5.36% | $27.18B | +19.50% | 1.03% |
Yahoo
LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels. A premarket approval application will be filed soon.
Yahoo
LONDON, November 14, 2024--LivaNova PLC announced Vladimir Makatsaria, CEO, will present a general business update during fireside chats at Stifel, Wolfe and Piper in New York.
Yahoo
Leerink analysts said the results were largely in line with outcomes in a trial of Inspire Medical’s rival device but cautioned that Livanova may have a hard time breaking into the sleep apnea market.
Yahoo
With the presidential election season behind us, a major source of uncertainty has been lifted, creating an ideal opportunity for investors to reassess their stock portfolios in light of shifting market conditions. In this environment, Goldman Sachs analysts are evaluating individual stocks, pinpointing those best positioned to thrive in a growth-oriented market. We’ve used the TipRanks database to pull up the details on two names that Goldman’s analysts have singled out. Looking at the broader
Yahoo
LivaNova PLC's ( NASDAQ:LIVN ) earnings announcement last week was disappointing for investors, despite the decent...
Yahoo
LONDON, November 11, 2024--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VNDA | 0.01% | $286.88M | +42.61% | 0.00% |
LFVN | 0.08% | $169.84M | +130.61% | 1.10% |
NAT | 0.16% | $636.83M | -30.05% | 13.79% |
LQDA | 0.16% | $859.91M | +53.94% | 0.00% |
ZCMD | 0.19% | $2.80M | -88.67% | 0.00% |
ABEO | 0.20% | $256.04M | +41.25% | 0.00% |
WPRT | -0.22% | $76.83M | -36.88% | 0.00% |
PSN | 0.23% | $10.03B | +50.06% | 0.00% |
VHC | -0.24% | $19.06M | -38.36% | 0.00% |
GAN | 0.25% | $83.39M | +21.19% | 0.00% |
EYPT | -0.27% | $492.90M | +50.49% | 0.00% |
K | 0.28% | $27.77B | +52.50% | 2.79% |
PULM | 0.29% | $19.83M | +202.98% | 0.00% |
ASC | 0.29% | $517.16M | -7.62% | 8.45% |
RLMD | -0.30% | $89.92M | +1.36% | 0.00% |
GCT | 0.32% | $983.16M | +147.95% | 0.00% |
HURN | 0.34% | $2.13B | +14.70% | 0.00% |
MIST | 0.38% | $92.79M | -32.56% | 0.00% |
GPCR | -0.38% | $1.88B | -36.14% | 0.00% |
ERIE | 0.38% | $19.39B | +46.23% | 1.23% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DFNM | 0.03% | $1.40B | 0.17% |
FLMI | 0.17% | $356.19M | 0.3% |
BCD | -0.28% | $245.02M | 0.3% |
CANE | -0.33% | $17.72M | 0.29% |
PREF | 0.47% | $999.92M | 0.55% |
SGOV | 0.60% | $27.53B | 0.09% |
CMDY | -0.61% | $279.14M | 0.28% |
HYMB | 0.66% | $2.81B | 0.35% |
HIGH | -0.72% | $302.78M | 0.51% |
FTSM | 1.29% | $6.08B | 0.45% |
GCC | -1.35% | $133.23M | 0.55% |
SMB | -1.63% | $266.77M | 0.07% |
TLTW | 1.84% | $1.09B | 0.35% |
BOXX | -2.08% | $4.43B | 0.1949% |
DBA | -2.09% | $755.88M | 0.93% |
USCI | -2.14% | $185.47M | 1.07% |
XBIL | 2.39% | $637.70M | 0.15% |
UNG | -2.44% | $908.80M | 1.06% |
FMB | 2.46% | $2.03B | 0.65% |
GBIL | 2.49% | $5.60B | 0.12% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -29.16% | $388.04M | 1.43% |
VIXY | -21.80% | $195.31M | 0.85% |
TAIL | -16.52% | $67.98M | 0.59% |
USDU | -15.90% | $201.97M | 0.5% |
DBE | -13.57% | $50.13M | 0.77% |
DBO | -12.55% | $217.57M | 0.77% |
KRBN | -12.25% | $242.47M | 0.85% |
UUP | -11.81% | $309.25M | 0.77% |
COMT | -11.72% | $829.06M | 0.48% |
CTA | -11.65% | $350.27M | 0.78% |
GSG | -11.26% | $914.42M | 0.75% |
KMLM | -11.25% | $353.87M | 0.9% |
EQLS | -9.65% | $76.08M | 1% |
MUST | -8.92% | $410.00M | 0.23% |
JUCY | -7.94% | $324.29M | 0.6% |
PDBC | -7.83% | $4.40B | 0.59% |
DBC | -7.05% | $1.39B | 0.87% |
CORN | -6.35% | $61.12M | 0.2% |
WEAT | -5.73% | $120.27M | 0.28% |
PWZ | -5.44% | $697.36M | 0.28% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XHE | 49.94% | $213.41M | 0.35% |
RSPA | 47.18% | $273.87M | 0% |
FSMD | 43.87% | $583.89M | 0.15% |
FIW | 43.79% | $1.86B | 0.53% |
SCHM | 43.52% | $11.59B | 0.04% |
SMMV | 43.43% | $321.07M | 0.2% |
XMLV | 43.29% | $976.94M | 0.25% |
IWC | 43.16% | $933.99M | 0.6% |
RIET | 43.01% | $88.96M | 0.5% |
JMEE | 42.95% | $1.51B | 0.24% |
ESML | 42.91% | $1.90B | 0.17% |
XSLV | 42.90% | $322.27M | 0.25% |
PBE | 42.89% | $258.53M | 0.58% |
IWN | 42.86% | $13.17B | 0.24% |
PHO | 42.81% | $2.27B | 0.59% |
NUSC | 42.77% | $1.27B | 0.31% |
IWS | 42.62% | $13.85B | 0.23% |
PINK | 42.62% | $161.15M | 0.5% |
PSC | 42.46% | $702.17M | 0.38% |
VXF | 42.39% | $21.54B | 0.06% |